ADAP

Adaptimmune Therapeutics

78 hedge funds and large institutions have $116M invested in Adaptimmune Therapeutics in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 24 reducing their positions, and 17 closing their positions.

Holders
78
Holders Change
-10
Holders Change %
-11.36%
% of All Funds
1.24%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
7
Increased
16
Reduced
24
Closed
17
Calls
Puts
Net Calls
Net Calls Change
Name Market Value Shares Shares
Change
Shares
Change %
IRC
76
Investors Research Corp
Georgia
$78 100 -100 -50%
BHWM
77
Beaird Harris Wealth Management
Texas
$72 92
Acadian Asset Management
78
Acadian Asset Management
Massachusetts
-358,010 Closed
Marshall Wace
79
Marshall Wace
United Kingdom
-272,681 Closed
Dimensional Fund Advisors
80
Dimensional Fund Advisors
Texas
-88,580 Closed
DC
81
Diametric Capital
Massachusetts
-78,441 Closed
T. Rowe Price Associates
82
T. Rowe Price Associates
Maryland
-73,922 Closed
GCP
83
GSA Capital Partners
United Kingdom
-34,307 Closed
PCM
84
Prelude Capital Management
New York
-25,181 Closed
PCS
85
Personal CFO Solutions
New Jersey
-19,388 Closed
NDSI
86
Newman Dignan & Sheerar Inc
Rhode Island
-19,364 Closed
Group One Trading
87
Group One Trading
Illinois
-16,541 Closed
CIC
88
Cornercap Investment Counsel
Georgia
-13,166 Closed
BRWA
89
B. Riley Wealth Advisors
Florida
-12,060 Closed
NCM
90
Narwhal Capital Management
Georgia
-10,344 Closed
CSS
91
Cubist Systematic Strategies
Connecticut
-10,049 Closed
Simplex Trading
92
Simplex Trading
Illinois
-9,408 Closed
WAM
93
Worth Asset Management
Texas
-600 Closed
SIC
94
Salem Investment Counselors
North Carolina
-52 Closed
Daiwa Securities Group
95
Daiwa Securities Group
Japan
$0 469
CFGS
96
Concourse Financial Group Securities
Alabama